Tejara Capital Ltd Acquires 108,500 Shares of Certara, Inc. $CERT

Tejara Capital Ltd grew its holdings in Certara, Inc. (NASDAQ:CERT) by 39.7% during the fourth quarter, Holdings Channel reports. The firm owned 381,552 shares of the company’s stock after acquiring an additional 108,500 shares during the quarter. Certara comprises about 0.8% of Tejara Capital Ltd’s holdings, making the stock its 25th largest position. Tejara Capital Ltd’s holdings in Certara were worth $3,361,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. First Horizon Corp acquired a new stake in Certara during the third quarter worth approximately $30,000. Versant Capital Management Inc lifted its stake in Certara by 66.7% in the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after buying an additional 1,153 shares during the period. Osaic Holdings Inc. lifted its stake in Certara by 50.7% in the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares during the period. Global Retirement Partners LLC boosted its holdings in shares of Certara by 45.0% during the 3rd quarter. Global Retirement Partners LLC now owns 5,636 shares of the company’s stock worth $69,000 after buying an additional 1,749 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Certara by 499.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after buying an additional 4,930 shares in the last quarter. Institutional investors own 73.96% of the company’s stock.

Certara Price Performance

Shares of NASDAQ:CERT opened at $4.61 on Friday. Certara, Inc. has a twelve month low of $4.59 and a twelve month high of $13.88. The stock’s 50 day moving average is $6.07 and its 200-day moving average is $7.85. The company has a quick ratio of 2.05, a current ratio of 1.88 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $717.18 million, a price-to-earnings ratio of -46.10 and a beta of 1.53.

Certara (NASDAQ:CERT) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). The business had revenue of $106.92 million during the quarter, compared to analyst estimates of $106.13 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The business’s revenue for the quarter was up .8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.14 EPS. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Sell-side analysts forecast that Certara, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Robert W. Baird lowered their price objective on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday. TD Cowen reissued a “buy” rating on shares of Certara in a research note on Thursday, February 26th. Barclays decreased their price target on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a research note on Tuesday. BMO Capital Markets dropped their price objective on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Tuesday. Finally, KeyCorp cut their price objective on shares of Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Certara presently has a consensus rating of “Hold” and an average price target of $8.85.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.